02509nas a2200373   4500000000100000008004100001260001200042653003400054653003500088653003200123653003700155653001400192100001300206700001500219700001100234700001200245700001400257700001300271700001300284700001500297700001500312700001100327700001500338700001500353700001300368700001400381700001300395245012400408856006000532300001200592490000700604520151000611022001402121       2023                            d  c09/202310aDrug research and development10aInfectious diseases of poverty10aNeglected Tropical Diseases10aProduct development partnerships10aSwiss TPH1 aMäser P1 aBernhard S1 aBrun R1 aBurri C1 aGagneux S1 aHetzel M1 aKaiser M1 aLengeler C1 aPluschke G1 aReus E1 aRottmann M1 aUtzinger J1 aWarryn L1 aWittlin S1 aKeiser J00aKey Contributions by the Swiss Tropical and Public Health Institute Towards New and Better Drugs for Tropical Diseases.  uhttps://www.chimia.ch/chimia/article/view/2023_593/6293  a593-6020 v773 a<p>Thanks to its expertise in clinical research, epidemiology, infectious diseases, microbiology, parasitology, public health, translational research and tropical medicine, coupled with deeply rooted partnerships with institutions in low- and middle-income countries (LMICs), the Swiss Tropical and Public Health Institute (Swiss TPH) has been a key contributor in many drug research and development consortia involving academia, pharma and product development partnerships. Our know-how of the maintenance of parasites and their life-cycles in the laboratory, plus our strong ties to research centres and disease control programme managers in LMICs with access to field sites and laboratories, have enabled systems for drug efficacy testing in vitro and in vivo, clinical research, and modelling to support the experimental approaches. Thus, Swiss TPH has made fundamental contributions towards the development of new drugs - and the better use of old drugs - for neglected tropical diseases and infectious diseases of poverty, such as Buruli ulcer, Chagas disease, food-borne trematodiasis (e.g. clonorchiasis, fascioliasis and opisthorchiasis), human African trypanosomiasis, leishmaniasis, malaria, schistosomiasis, soil-transmitted helminthiasis and tuberculosis. In this article, we show case the success stories of molecules to which Swiss TPH has made a substantial contribution regarding their use as anti-infective compounds with the ultimate aim to improve people's health and well-being.</p>
  a0009-4293